Haemonetics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +35.5% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 7.9% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation D
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 53.2x | Better than 9% |
| Forward P/E | 27.5x | Better than 21% |
| Price / Sales | 4.0x | Better than 29% |
| P/E vs own 5-yr range | 78th pctl | Better than 28% |
Growth B
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 4.5% | Better than 45% |
| Net income CAGR (3Y) | -5.5% | Better than 32% |
| Free cash flow CAGR (3Y) | 47.2% | Better than 83% |
Profitability B
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 59.0% | Better than 73% |
| Operating margin | 18.1% | Better than 72% |
| Net margin | 7.3% | Better than 51% |
| Return on equity | 12.0% | Better than 59% |
| Return on invested capital | 5.9% | Better than 49% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 10.4% | Better than 90% |
| 6-month return | 83.5% | Better than 99% |
| 12-month return (ex latest month) | 50.4% | Better than 83% |
| Distance below 52-week high | 9.0% | Better than 86% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.0x | Better than 72% |
| Debt to assets | 51.1% | Better than 14% |
| Interest coverage | 5.5x | Better than 58% |
| Free cash flow / net income | 267.6% | Better than 84% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 80.0% | Better than 58% |
| Upside to average target | 21.3% | Better than 35% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 120.37
- Open
- 120.37
- Day range
- 119.68 - 122.34
- Avg price
- 120.30
- Volume
- 382.96K
- Turnover
- 46.07M
- Turnover ratei
- 0.85%
- Volume ratioi
- 0.74
- Amplitudei
- 2.21%
- 52-week rangei
- 51.00 - 132.00
Valuation
- P/Ei
- 58.61
- P/E (TTM)i
- 53.17
- P/Bi
- 6.09
- EPSi
- 2.05
- Book value / shi
- 19.73
- Net profit
- 93.35M
- Net assets
- 898.50M
Share structure
- Market cap
- 5.47B
- Float capi
- 5.40B
- Shares out
- 45.54M
- Float sharesi
- 44.93M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
9.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+5.65M net over the window
Short interest
- Shares short
- 3.60M
- % of floati
- 7.91%
- Days to coveri
- 6.27
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Haemonetics (HAE)?
Haemonetics last traded at 120.16. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Haemonetics's market cap?
About 5.47B.
What is the P/E ratio of Haemonetics?
The trailing twelve-month P/E is 53.17, above its own 5-year average of 42.15 — toward the top of its historical range (78.15% percentile). See the Valuation tab for the full history.
Does Haemonetics pay a dividend?
Haemonetics does not currently pay a regular dividend.
Is Haemonetics a buy according to analysts?
The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 145.75, which implies 21.3% upside from the current price. This is not investment advice.
What is Haemonetics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Haemonetics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Haemonetics discussion 0 comments